| General Information | |
|---|---|
| ZINC ID | ZINC000040420610 |
| Molecular Weight (Da) | 479 |
| SMILES | Cc1c(C(=O)N(C)C(=O)C(C)(C)C)nn(-c2ccc(Cl)cc2Cl)c1-c1ccc(Cl)cc1 |
| Molecular Formula | C23Cl3N3O2 |
| Action | Antagonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 125.489 |
| HBA | 3 |
| HBD | 0 |
| Rotatable Bonds | 4 |
| Heavy Atoms | 31 |
| LogP | 7.185 |
| Activity (Ki) in nM | 218.776 |
| Polar Surface Area (PSA) | 55.2 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | + |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | - |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | - |
| Cyp2c9 inhibition | + |
| Cyp2c19 inhibition | + |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | - |
| Acute oral toxicity | + |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | - |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 0.83816897 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 17 |
| Fraction csp3 | 0.26 |
| Ilogp | 4.07 |
| Xlogp3 | 6.78 |
| Wlogp | 6.45 |
| Mlogp | 5.21 |
| Silicos-it log p | 5.79 |
| Consensus log p | 5.66 |
| Esol log s | -7.09 |
| Esol solubility (mg/ml) | 0.0000389 |
| Esol solubility (mol/l) | 8.13E-08 |
| Esol class | Poorly sol |
| Ali log s | -7.75 |
| Ali solubility (mg/ml) | 0.00000859 |
| Ali solubility (mol/l) | 1.79E-08 |
| Ali class | Poorly sol |
| Silicos-it logsw | -8.36 |
| Silicos-it solubility (mg/ml) | 0.00000211 |
| Silicos-it solubility (mol/l) | 4.41E-09 |
| Silicos-it class | Poorly soluble |
| Pgp substrate | |
| Log kp (cm/s) | -4.41 |
| Lipinski number of violations | 1 |
| Ghose number of violations | 1 |
| Veber number of violations | 0 |
| Egan number of violations | 1 |
| Muegge number of violations | 1 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 2 |
| Synthetic accessibility | 3.32 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -6.998 |
| Logd | 5.02 |
| Logp | 5.871 |
| F (20%) | 0.002 |
| F (30%) | 0.004 |
| Mdck | - |
| Ppb | 98.67% |
| Vdss | 1.061 |
| Fu | 2.04% |
| Cyp1a2-inh | 0.296 |
| Cyp1a2-sub | 0.951 |
| Cyp2c19-inh | 0.894 |
| Cyp2c19-sub | 0.902 |
| Cl | 3.316 |
| T12 | 0.038 |
| H-ht | 0.136 |
| Dili | 0.967 |
| Roa | 0.117 |
| Fdamdd | 0.118 |
| Skinsen | 0.039 |
| Ec | 0.003 |
| Ei | 0.009 |
| Respiratory | 0.013 |
| Bcf | 3.519 |
| Igc50 | 4.988 |
| Lc50 | 6.56 |
| Lc50dm | 5.697 |
| Nr-ar | 0.038 |
| Nr-ar-lbd | 0.01 |
| Nr-ahr | 0.468 |
| Nr-aromatase | 0.805 |
| Nr-er | 0.858 |
| Nr-er-lbd | 0.612 |
| Nr-ppar-gamma | 0.013 |
| Sr-are | 0.869 |
| Sr-atad5 | 0.01 |
| Sr-hse | 0.025 |
| Sr-mmp | 0.924 |
| Sr-p53 | 0.827 |
| Vol | 450.534 |
| Dense | 1.059 |
| Flex | 0.316 |
| Nstereo | 0 |
| Nongenotoxic carcinogenicity | 1 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 0 |
| Surechembl | 0 |
| Nonbiodegradable | 4 |
| Skin sensitization | 1 |
| Acute aquatic toxicity | - |
| Toxicophores | 3 |
| Qed | 0.434 |
| Synth | 2.659 |
| Fsp3 | 0.261 |
| Mce-18 | 24 |
| Natural product-likeness | -1.208 |
| Alarm nmr | 0 |
| Bms | 1 |
| Chelating | 0 |
| Pfizer | - |
| Gsk | Rejected |
| Goldentriangle | Rejected |